Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Sarcoma 4Neoplasms 4Neoplasm Metastasis 4Hematologic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Glioma 3Thyroid Cancer, Papillary 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Leukemia, Myeloid, Acute 2Central Nervous System Neoplasms 2Wilms Tumor 1Uveal Melanoma 1Thrombocytosis 1Solid Tumors 1Solid Tumor 1Sarcoma, Ewing 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Noonan Syndrome 6 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Thyroid Cancer Patients Who Received Target Therapy × entrectinib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡